Average Co-Inventor Count = 5.00
ph-index = 11
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (37 from 3,681 patents)
2. E. R. Squibb Sons, Inc. (2 from 1,624 patents)
3. Bristol Meyers Squibb Company (1 from 41 patents)
40 patents:
1. 12240840 - Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
2. 12157733 - Aminotriazolopyridines as kinase inhibitors
3. 12110290 - Triazolopyridinyl compounds as kinase inhibitors
4. 11884650 - Substituted heterocyclic compounds
5. 11866414 - Substituted heterocyclic compounds
6. 11767322 - Triazolopyridinyl compounds as kinase inhibitors
7. 11440913 - Aminoimidazopyridazines as kinase inhibitors
8. 11299494 - Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
9. 10913738 - Aminotriazolopyridines as kinase inhibitors
10. 10836770 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
11. RE47929 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
12. 10000480 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
13. 9505748 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
14. 9221826 - Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
15. 8987268 - Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases